Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 5,215 Cr.
- Current Price ₹ 911
- High / Low ₹ 1,260 / 648
- Stock P/E 40.2
- Book Value ₹ 168
- Dividend Yield 0.00 %
- ROCE 14.6 %
- ROE 14.3 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.7% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|
356 | 373 | 411 | 801 | 926 | 1,081 | 1,244 | 1,301 | |
315 | 322 | 356 | 704 | 813 | 927 | 1,057 | 1,105 | |
Operating Profit | 41 | 51 | 54 | 96 | 114 | 154 | 186 | 196 |
OPM % | 11% | 14% | 13% | 12% | 12% | 14% | 15% | 15% |
0 | 1 | 1 | 3 | 9 | 12 | 12 | 14 | |
Interest | 6 | 5 | 4 | 6 | 20 | 21 | 2 | 5 |
Depreciation | 11 | 10 | 6 | 8 | 11 | 16 | 25 | 31 |
Profit before tax | 25 | 38 | 46 | 86 | 92 | 130 | 171 | 174 |
Tax % | 20% | 26% | 26% | 25% | 26% | 27% | 25% | |
20 | 28 | 34 | 64 | 68 | 94 | 128 | 130 | |
EPS in Rs | 165.67 | 232.42 | 287.50 | 532.92 | 14.16 | 16.49 | 22.41 | 22.69 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 16% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 36% |
3 Years: | 26% |
TTM: | 22% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 32% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 17% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 12 | 48 | 57 | 57 |
Reserves | 70 | 98 | 133 | 197 | 229 | 774 | 902 |
72 | 54 | 46 | 199 | 237 | 245 | 338 | |
68 | 81 | 179 | 167 | 191 | 240 | 271 | |
Total Liabilities | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 |
78 | 73 | 79 | 183 | 183 | 358 | 830 | |
CWIP | 0 | 0 | 7 | 0 | 22 | 341 | 23 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
144 | 172 | 283 | 392 | 500 | 617 | 716 | |
Total Assets | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
19 | 31 | 42 | 59 | 67 | 146 | 64 | |
-9 | -6 | -20 | -188 | -91 | -499 | -152 | |
-9 | -23 | -19 | 125 | 27 | 361 | 92 | |
Net Cash Flow | 1 | 1 | 3 | -5 | 3 | 8 | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 93 | 85 | 123 | 97 | 104 | 97 | 97 |
Inventory Days | 50 | 84 | 107 | 76 | 77 | 91 | 119 |
Days Payable | 80 | 92 | 132 | 86 | 105 | 113 | 115 |
Cash Conversion Cycle | 64 | 77 | 99 | 87 | 77 | 75 | 101 |
Working Capital Days | 30 | 45 | 39 | 37 | 58 | 77 | 81 |
ROCE % | 26% | 28% | 31% | 24% | 19% | 15% |
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 (The 'Listing Regulations').
21 Aug - Agreement dated 21 Aug 2025 to buy ~20 bighas in Baddi; total consideration ₹19.5 crore (₹10 crore paid).
-
Pursuant To The Regulation 30 (Read With Part A Of Schedule III) And Other Applicable Provisions Of SEBI (LODR) Regulations, 2015, ('Listing Regulations'), We Hereby Inform That The Company Has Successfully Completed The Inspection Of Its Cephalosporin Plant, Baddi, Himachal Pradesh Conducted By The United Kingdom Medicines And Healthcare Products Regulatory Agency ('UK-MHRA')
20 Aug - UK-MHRA inspected Baddi cephalosporin plant (18–20 Aug 2025); no critical/major observations.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
13 Aug - Transcript of Investor /Analyst Call Earnings Call held on Friday 08th August 2025
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
8 Aug - Audio recording of Q1 FY2026 earnings call available on company website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Aug - The Board of the Company at its meeting held on Thursday 07th August 2025 has approved the unaudited (Standalone and Consolidated) Financial Results of the …
Concalls
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain